Kevin Kumler’s Post

A new intervention for TARGETing resistant hypertension: Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial https://ow.ly/c1SV50TL3Oi #ISN-GTF #ClinicalTrials

Our last review on drug intolerance: Multiple drug intolerance in antihypertensive patients: what is known and what is missing Journal of Hypertension ():10.1097/HJH.0000000000003737, April 12, 2024. | DOI: 10.1097/HJH.0000000000003737

Chronic Kidney Disease (CKD) is a silent condition that affects millions, gradually diminishing the kidneys' ability to perform their vital roles—from filtering waste to balancing minerals and maintaining blood pressure. With CKD often undetected until advanced stages due to subtle symptoms, awareness and early detection become crucial. The condition escalates through five stages, with risk factors including diabetes, hypertension, obesity, and family history, underscoring the importance of regular check-ups. Understanding CKD's causes, from autoimmune diseases to inherited conditions, empowers us to seek timely medical advice. Diagnosis through simple blood and urine tests can pave the way for effective management strategies, emphasizing the significance of lifestyle adjustments and specialized treatments in mitigating progression and enhancing quality of life. Let's unite in raising awareness about CKD, and advocating for early screening and comprehensive care to combat this pervasive health challenge. Visit https://lnkd.in/ehSvdDy to learn more. . . . . . #ckd #kidneydisease #kidneyhealth #kidney #chronickidneydisease #pharma #pharmainuae #healthcareawareness #healthcare #pharmaindustry #uae #uaepharma #gulf #innovativedrugs #distribution #menaregion #mena #pharmaceuticals #pharma #drugs #patients #medicines #pharmasolutionsuae

HR Leaders: It's going to be more and more difficult to not cover these new GLP1 medications. Rather than only covering them for diabetes, there are other options. Lark Health has a solution set which ensures the right treatment is matched to each unique person, and them means better outcomes and lower costs. Let's talk!

This WebMD article highlights the benefits of established FDA-approved, weight-management medications including a VIVUS treatment option. WebMD notes that compared to newer treatments, these medications can be cost-friendly, safe, and effective weight-loss options. The article notes that because patients may need to take obesity medications for longer periods of time, cost-friendly medications can be a valuable treatment option. WebMD cites a 2022 independent assessment by the Institute for Clinical and Economic Review found that VIVUS’ weight-management medication is the most cost-effective chronic weight-management medication among semaglutide and other obesity drugs that came before it. Read the article at: https://wb.md/3UG7cDZ VIVUS is committed to advancing treatment options for obesity and offering much-needed hope to patients globally. To learn more about our work in this area, please visit VIVUS.com. #treatingobesity #obesitymedicine #vivusllc #weightmanagement #weightlossmedications

As a prescriber, I was not surprised to read in an article nearly 1 out of 8 US adult population has been using GLP-1 or GLP1/ GIP! The growing public popularity is closely related to the accumulating scientific knowledge that GLP-1 or GLP1/ GIP is game changer not only for the management of diabetes but also for addressing underlying obesity with strong or potential benefits for underlying cardio-vascular and cardio-metabolic diseases. https://lnkd.in/emAzPgYe The obstacles reaching out to the medications may make the compounded products more popular! However, those compounded products marketed as "semaglutide" might not actually contain the same active component as those that have FDA approval, and the results might not be what you were hoping for. https://lnkd.in/eDxG8KBY

On World Diabetes Day, we come together to raise awareness about diabetes and the importance of managing this global health challenge. Whether it's through education, prevention, or treatment, every step counts in the fight against diabetes. Let’s prioritize healthy lifestyles, early detection, and better access to care for those affected. Together, we can make a difference and reduce the impact of diabetes worldwide. Stay informed and take action for a healthier future. To know more about us visit www.jeevanscientific.com #WorldDiabetesDay #DiabetesAwareness #HealthMatters #PreventDiabetes #medicine #medical #pharmaceuticals #pharma #clinical #clinicaltrials #JSTL #Jeevanscientifictechnologylimited #Jeevanscientific #clinicalresearch

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. However, the drug is now being marketed as a heart drug. So will Medicare start covering the drug? Read on to find out. #wegovy #ozempic #medicare #obesity #heartdisease https://lnkd.in/dEnVRwRY

Chronic pain medication cost is a challenge, especially for sickle cell and cancer patients, leaving them in persistent agony. The escalating prices burden patients, particularly in Africa, where limited funding hinders access. High costs not only prevent purchasing but also lead to impoverishing expenses for pain treatment. Many sufferers can't afford essential medications. This is why 10mg Pharma is bridging the gap to affordable chronic pain medication in Africa by providing quality and affordable chronic pain medications as well as providing finances to this healthcare providers. Want to find out more? Visit our website👇 www.10mg.co.uk   #pain #chronicpain #paininafrica #painmanagement #chronicpainmanageme

Pseudoephedrine-Induced Risks of PRES and RCVS Pseudoephedrine is a sympathomimetic drug used as a nasal/sinus decongestant in common cold remedies. Few cases of Pseudoephedrine-associated posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) have been reported to MHRA of UK and PRAC and CHMP of EMA. Health care professionals should be aware of pseudoephedrine-associated PRES and RCVS. Patients with severe or uncontrolled hypertension or those with severe acute or chronic renal disease should avoid using products containing pseudoephedrine. https://lnkd.in/g5wcA-kt https://lnkd.in/g5QKu3JP https://lnkd.in/gqKMkyCD https://lnkd.in/gqEF6egM